REVELATION BIOSCIENCES INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
REVB$4.11+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| March 31,2024 | December 31,2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $14,551,740 | $11,991,701 |
| Deferred offering costs | — | 71,133 |
| Prepaid expenses and other current assets | 71,876 | 84,691 |
| Total current assets | 14,623,616 | 12,147,525 |
| Property and equipment, net | 77,994 | 65,084 |
| Total assets | $14,701,610 | $12,212,609 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $1,681,665 | $1,359,898 |
| Accrued expenses | 620,280 | 1,152,460 |
| Deferred underwriting commissions | 2,911,260 | 2,911,260 |
| Warrant liability | 15,260 | 141,276 |
| Total current liabilities | 5,228,465 | 5,564,894 |
| Total liabilities | 5,228,465 | 5,564,894 |
| Commitments and Contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Common Stock, $0.001 par value; 500,000,000 shares authorized at March 31, 2024 and December 31, 2023 and 1,632,935 and 264,537 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 1,633 | 265 |
| Additional paid-in-capital | 37,620,047 | 32,114,552 |
| Accumulated deficit | (28,148,535) | (25,467,102) |
| Total stockholders’ equity | 9,473,145 | 6,647,715 |
| Total liabilities and stockholders’ equity | $14,701,610 | $12,212,609 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.